If Not Now, When? Chloroquine/Hydroxychloroquine dosage for COVID-19 should be clarified especially in view of higher mortality in the elderly.

With international Colleagues, we have discussed the present lack of chemotherapeutic agents confirmed by RCTs against the dramatic COVID-19 pandemics. However, the antimalarial drug hydroxychloroquine (HCQ) has shown some encouraging preliminary results at higher dosages and if given in the initial phases of the infection. A brief review of the recently published literature strongly suggest that HCQ should be given to patients at a dosage of at least 600 mg/day. We have briefly discussed how such treatments could improve survival after SARS-CoV-2 infection for both patients and medical/paramedic personnel. As per the title, this paper strongly suggests that HCQ efficacy should be tested now, in the midst of this dramatic pandemics.